ProJenX Announces Formation of Clinical Advisory Board - PR Newswire
ProJenX, Inc. forms Clinical Advisory Board (ClAB) with experts in ALS and neurodegenerative diseases to guide clinical development of prosetin, a novel brain-penetrant MAP4K inhibitor. Prosetin is being evaluated in Study PRO-101, a Phase 1 trial assessing safety and tolerability in healthy volunteers and ALS participants, with positive early results.
Highlighted Terms
Related News
ProJenX Announces Formation of Clinical Advisory Board - PR Newswire
ProJenX, Inc. forms Clinical Advisory Board (ClAB) with experts in ALS and neurodegenerative diseases to guide clinical development of prosetin, a novel brain-penetrant MAP4K inhibitor. Prosetin is being evaluated in Study PRO-101, a Phase 1 trial assessing safety and tolerability in healthy volunteers and ALS participants, with positive early results.